SHANGHAI – New out of the gate, Suzhou Neupharma Co. Ltd., has put its first candidate, RX-108, into clinical trials. Like many companies in China with global ambitions, Neupharma is collecting its first-in-human data in Australia while it waits for its trials to get a green light in China. (See Beigene story this issue.)